

# Deepak C D'souza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8684744/publications.pdf>

Version: 2024-02-01

58  
papers

3,642  
citations

218592

26  
h-index

189801

50  
g-index

61  
all docs

61  
docs citations

61  
times ranked

4257  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of circulating exosomes reveals a peripheral signature of astrocytic pathology in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 33-45.	1.3	19
2	<i>Letter to the Editor:</i> Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 898-900.	1.5	3
3	Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. <i>Neuropsychopharmacology</i> , 2022, 47, 1574-1581.	2.8	41
4	Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate". <i>American Journal of Psychiatry</i> , 2022, 179, 8-10.	4.0	17
5	Editorial: Gone to Pot: Examining the Association Between Cannabis Use and Medical/Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 837757.	1.3	0
6	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 719-742.	1.3	40
7	Editorial. <i>Psychopharmacology</i> , 2022, , 1.	1.5	0
8	Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior. <i>Cannabis and Cannabinoid Research</i> , 2022, , .	1.5	0
9	Psychedelics: Old trips, new destinations in psychopharmacology research. <i>Psychopharmacology</i> , 2022, , 1.	1.5	0
10	Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1854-1862.	2.8	64
11	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	4.1	32
12	A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. <i>Neuropsychopharmacology</i> , 2021, 46, 478-485.	2.8	22
13	Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. <i>Neurotherapeutics</i> , 2021, 18, 534-543.	2.1	54
14	In vivo evidence of lower synaptic vesicle density in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 7690-7698.	4.1	51
15	Exocannabinoids, Endocannabinoids, and Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 600-602.	1.1	0
16	Differential Cognitive Performance in Females and Males with Regular Cannabis Use. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 570-580.	1.2	6
17	Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. <i>NeuroImage</i> , 2021, 237, 118167.	2.1	18
18	Association of Cannabis Use During Adolescence With Neurodevelopment. <i>JAMA Psychiatry</i> , 2021, 78, 1031.	6.0	82

#	ARTICLE	IF	CITATIONS
19	Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. <i>Psychological Medicine</i> , 2020, 50, 2452-2459.	2.7	8
20	In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. <i>Psychopharmacology</i> , 2020, 237, 3097-3107.	1.5	7
21	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	1.6	49
22	Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 559-570.	1.0	23
23	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 344-353.	3.7	147
24	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. <i>Neuropsychopharmacology</i> , 2020, 45, 990-997.	2.8	127
25	Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. <i>Scientific Reports</i> , 2020, 10, 3450.	1.6	17
26	S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGING. <i>Schizophrenia Bulletin</i> , 2019, 45, S310-S311.	2.3	0
27	Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. <i>Psychopharmacology</i> , 2019, 236, 3209-3219.	1.5	8
28	20.1 BEHAVIORAL, COGNITIVE, AND PSYCHOPHYSIOLOGICAL CHARACTERIZATION AND SHORT-TERM COURSE OF CANNABINOID- INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP). <i>Schizophrenia Bulletin</i> , 2019, 45, S121-S122.	2.3	0
29	Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis. <i>Psychopharmacology</i> , 2019, 236, 2635-2640.	1.5	4
30	O11.2. CHARACTERIZING CANNABINOID INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) AS A POSSIBLE SUBTYPE OF SCHIZOPHRENIA USING DEEP LEARNING. <i>Schizophrenia Bulletin</i> , 2019, 45, S194-S194.	2.3	0
31	Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. <i>Lancet Psychiatry</i> , 2019, 6, 35-45.	3.7	125
32	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. <i>Biological Psychiatry</i> , 2018, 84, 413-421.	0.7	43
33	Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. <i>Neuropharmacology</i> , 2018, 135, 412-423.	2.0	23
34	Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?. <i>Schizophrenia Research</i> , 2018, 195, 455-462.	1.1	4
35	Revisiting the Consequences of Adolescent Cannabinoid Exposure Through the Lens of the Endocannabinoid System. <i>Current Addiction Reports</i> , 2018, 5, 418-427.	1.6	3
36	The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol ( $\Delta^9$ -THC) in humans. <i>Journal of Psychopharmacology</i> , 2018, 32, 1308-1318.	2.0	27

#	ARTICLE	IF	CITATIONS
37	17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.. Schizophrenia Bulletin, 2018, 44, S27-S27.	2.3	1
38	39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY. Schizophrenia Bulletin, 2018, 44, S63-S63.	2.3	1
39	Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 176-183.	2.5	27
40	Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology, 2016, 233, 3503-3512.	1.5	101
41	The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients. Psychiatric Quarterly, 2016, 87, 177-187.	1.1	17
42	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological Psychiatry, 2016, 79, 997-1005.	0.7	83
43	Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry, 2016, 79, 526-538.	0.7	113
44	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. JAMA Psychiatry, 2015, 72, 316.	6.0	304
45	The Psychosis-like Effects of $\delta^9$ -Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans. Biological Psychiatry, 2015, 78, 805-813.	0.7	44
46	Problems With the Medicalization of Marijuana. JAMA - Journal of the American Medical Association, 2014, 311, 2377.	3.8	40
47	Medicalization of Marijuana—Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1931.	3.8	1
48	Disrupted Gamma-Band Neural Oscillations During Coherent Motion Perception in Heavy Cannabis Users. Neuropsychopharmacology, 2014, 39, 3087-3099.	2.8	23
49	Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports, 2014, 1, 115-128.	1.6	109
50	Spicing things up: synthetic cannabinoids. Psychopharmacology, 2013, 228, 525-540.	1.5	241
51	The Impact of NMDA Receptor Blockade on Human Working Memory-Related Prefrontal Function and Connectivity. Neuropsychopharmacology, 2013, 38, 2613-2622.	2.8	133
52	Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology, 2013, 38, 492-503.	2.8	67
53	Modelling psychosis. Psychopharmacology, 2009, 206, 513-514.	1.5	7
54	Blunted Psychotomimetic and Amnesic Effects of $\delta^9$ -Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology, 2008, 33, 2505-2516.	2.8	225

#	ARTICLE	IF	CITATIONS
55	Greater vulnerability to the amnestic effects of ketamine in males. <i>Psychopharmacology</i> , 2006, 187, 405-414.	1.5	43
56	The acute effects of cannabinoids on memory in humans: a review. <i>Psychopharmacology</i> , 2006, 188, 425-444.	1.5	441
57	Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. <i>Psychopharmacology</i> , 2005, 179, 136-143.	1.5	33
58	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. <i>Biological Psychiatry</i> , 2005, 57, 594-608.	0.7	524